Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS

참고문헌 (118)

1. "WHO Coronavirus Dashboard" (2021)[URL]
2. "Centers for Disease Control and Prevention COVID-19" (2021)[URL]
3. Seyed Hosseini, E., "The novel coronavirus Disease-2019 (COVID-19):mechanism of action, detection and recent therapeutic strategies", Virology, 551, pp.1~9 (2020)
4. Wong, S. K., "A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2", J. Biol. Chem, 279, pp.3197~3201 (2004)
5. Tufan, A., "COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs", Turk. J. Med. Sci, 50, pp.620~632 (2020)
6. Ferini-Strambi, L., "COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?", J. Neurol, 268, pp.409~419 (2021)
7. Zhou, Y., "Network medicine links SARS-CoV-2", COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment, 2021, pp.13, 110~
8. Wang, Q., "COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US", Alzheimer’s Dement, 17, pp.1297~1306 (2021)
9. Krey, L., "SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson’s Disease?", Brain Sci, 11, pp.1654~ (2021)
10. Matthews, K. A., "Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States(2015-2060)in adults aged >", =65 years, 2019, pp.15, 17~24
11. Marras, C., "Prevalence of Parkinson’s disease across North America", NPJ Parkinson’s Dis, 4, pp.21~ (2018)
12. John, A., "Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria", Ageing Res. Rev, 65, pp.101208~ (2021)
13. Beitz, J. M., "Parkinson’s disease : a review", Front. Biosci. Scholar Ed, 6, pp.65~74 (2014)
14. Gomez-Benito, M., "Modeling Parkinson’s Disease With the Alpha-Synuclein Protein", Front. Pharmacol, 11, pp.356~ (2020)
15. Oliveira-Nascimento, L., "The Role of TLR2 in Infection and Immunity", Front. Immunol, 3, pp.79~ (2012)
16. Liu, S., "TLR2 is a primary receptor for Alzheimer’s amyloid beta peptide to trigger neuroinflammatory activation", J. Immunol, 188, pp.1098~1107 (2012)
17. Kim, C., "Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia", Nat. Commun, 4, pp.1562~ (2013)
18. 권소민, "Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies", Experimental Neurobiology, 28(5), pp.547~553 (2019), 한국뇌신경과학회
19. Rangasamy, S. B., "Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer’s pathology", J. Clin. Investig, 128, pp.4297~4312 (2018)
20. Lax, N., "Systemic microbial TLR2agonists induce neurodegeneration in Alzheimer’s disease mice", J. Neuroinflammation, 17, pp.55~ (2020)
21. Kim, C., "Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation", Mol. Neurodegener, 13, pp.43~ (2018)
22. Wang, D., "Clinical Characteristics of 138 Hospitalized Patients With 2019Novel Coronavirus-Infected Pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
23. McAbee, G. N., "Encephalitis Associated with COVID-19 Infection in an 11-Year-Old Child", Pediatr. Neurol, 109, pp.94~ (2020)
24. Moriguchi, T., "A first case of meningitis", encephalitis associated with SARSCoronavirus-2, 2020, pp.94, 55~58
25. Lodigiani, C., "Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy", Thromb. Res, 191, pp.9~14 (2020)
26. Al-Sarraj, S., "Invited review : the spectrum of neuropathology in COVID-19", Neuropathol. Appl. Neurobiol, 47, pp.3~16 (2021)
27. Song, E., "Neuroinvasion of SARS-CoV-2 in human and mouse brain", J. Exp. Med, 218, pp.e20202135~ (2021)
28. Norouzi, M., "Nervous System Involvement in COVID-19 : a review of the current knowledge", Mol. Neurobiol, 58, pp.3561~3574 (2021)
29. Dosch, S. F., "SARS coronavirus spike proteininduced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro", Virus Res, 142, pp.19~27 (2009)
30. Zheng, M., "TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines", Nat. Immunol, 22, pp.829~838 (2021)
31. "SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kappaB pathway" (2021)[URL]
32. Qian, Y., "Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin", J. Virol (2021)[DOI]
33. Xia, Y., "Reactive microglia enhance the transmission of exosomal alphasynuclein via toll-like receptor 2", Brain, 144, pp.2024~2037 (2021)
34. Caplan, I. F., "Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies", Front. Pharmacol, 9, pp.417~ (2018)
35. Kim, C., "LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies", Sci. Transl. Med, 12, pp.eaay0399~ (2020)
36. Kim Changyoun, "Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells", Experimental and Molecular Medicine, 53, pp.1~10 (2021), 생화학분자생물학회[DOI]
37. Harapan, B. N., "Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and coronavirus disease 19(COVID-19)", J. Neurol, 268, pp.3059~3071 (2021)
38. Maiese, A., "SARS-CoV-2 and the brain: a review of the current knowledge on neuropathology in COVID-19", Brain Pathol, 31, pp.e13013~ (2021)
39. Heneka, M. T., "Immediate and long-term consequences of COVID-19 infections for the development of neurological disease", Alzheimers Res. Ther, 12, pp.69~ (2020)
40. Matschke, J., "Neuropathology of patients with COVID-19 in Germany: a post-mortem case series", Lancet Neurol, 19, pp.919~929 (2020)
41. Liu, R., "Decreased T cell populations contribute to the increased severity of COVID-19", Clin. Chim. Acta, 508, pp.110~114 (2020)
42. Du, R. H., "Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2", Eur. Respir. J, 56, pp.2000524~ (2020)
43. Schwabenland, M., "Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions", Immunity, 54, pp.594~1610.e1511 (2021)
44. Solomon, I. H., "Neuropathological Features of Covid-19", N. Engl. J. Med, 383, pp.989~992 (2020)
45. Butowt, R., "Anosmia in COVID-19 : Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection", Neuroscientist, 27, pp.582~603 (2020)
46. Meinhardt, J., "Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19", Nat. Neurosci, 24, pp.168~175 (2021)
47. Armocida, D., "How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy", J. Clin. Neurosci, 79, pp.231~236 (2020)
48. McQuaid, C., "SARS-CoV-2: is there neuroinvasion?", Fluids Barriers CNS, 18, pp.32~ (2021)
49. Deng, W., "Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques", Nat. Commun, 11, pp.4400~ (2020)
50. Sun, K., "Atlas of ACE2 gene expression reveals novel insights into transmission of SARS-CoV-2", Heliyon, 7, pp.e05850~ (2021)
51. Casagrande, M., "Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19", Br. J. Ophthalmol (2021)[DOI]
52. Penkava, J., "Detection of SARS-CoV-2-RNA in post-mortem samples of human eyes", Graefes Arch. Clin. Exp. Ophthalmol (2021)[DOI]
53. Rhea, E. M., "The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice", Nat. Neurosci, 24, pp.368~378 (2021)
54. Erickson, M. A., "Interactions of SARS-CoV-2 with the Blood-Brain Barrier", Int. J. Mol. Sci, 22, pp.2681~ (2021)
55. Alexopoulos, H., "Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome : studies in 8 stuporous and comatose patients", Neurol. Neuroimmunol. Neuroinflamm, 7, pp.e893~ (2020)
56. Frontera, J. A., "Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer’s dementia", Alzheimers Dement (2022)[DOI]
57. Chiricosta, L., "SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer’s Disease Patients", Int. J. Mol. Sci, 22, pp.13603~ (2021)
58. Kasparian, K., "Commentary : APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort", Front. Immunol, 11, pp.1939~ (2020)
59. Safieh, M., "ApoE4 : an emerging therapeutic target for Alzheimer’s disease", BMC Med, 17, pp.64~ (2019)
60. Zhang, Q., "COVID-19 Case Fatality and Alzheimer’s Disease", J. Alzheimer’s Dis, 84, pp.1447~1452 (2021)
61. Brown, E. E., "Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer’s Disease and Related Dementias", Am. J. Geriatr. Psychiatry, 28, pp.712~721 (2020)
62. Boutoleau-Bretonniere, C., "The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer’s Disease During the COVID-19 Crisis", J. Alzheimer’s Dis, 76, pp.41~47 (2020)
63. Ni, W., "Role of angiotensin-converting enzyme 2(ACE2)in COVID-19", Crit. Care, 24, pp.422~ (2020)
64. Kehoe, P. G., "Angiotensinconverting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology", Alzheimer’s Res. Ther, 8, pp.50~ (2016)
65. Lim, K. H., "Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer’s disease", J. Infect, 81, pp.e33~e34 (2020)
66. Zhao, Y., "Ubiquity of the SARS-CoV-2 receptor ACE2 and upregulation in limbic regions of Alzheimer’s disease brain", Folia Neuropathol, 59, pp.232~238 (2021)
67. Fearon, C., "Parkinson’s Disease and the COVID-19 Pandemic", J. Parkinson’s Dis, 11, pp.431~444 (2021)
68. Merello, M., "SARS-CoV-2 and the risk of Parkinson’s disease : facts and fantasy", Lancet Neurol, 20, pp.94~95 (2021)
69. Lee, M. Y., "Prolonged Dysphagia After a COVID-19 Infection in a Patient With Parkinson Disease", Am. J. Phys. Med. Rehabil, 100, pp.837~839 (2021)
70. Jaiswal, V., "The Influence of Coronavirus Disease-2019(COVID-19)On Parkinson’s Disease : an updated systematic review", J. Prim. Care Community Health, 12, pp.21501327211039709~ (2021)
71. Semerdzhiev, S. A., "Interactions between SARS-CoV-2 N-Protein and alpha-Synuclein Accelerate Amyloid Formation", ACS Chem. Neurosci, 13, pp.143~150 (2022)
72. Helmich, R. C., "The Impact of the COVID-19 Pandemic on Parkinson’s Disease : Hidden Sorrows and Emerging Opportunities", J. Parkinson’s Dis, 10, pp.351~354 (2020)
73. Ellis, T., "Mobilizing Parkinson’s disease : the future of exercise", J. Parkinson’s Dis, 8, pp.S95~S100 (2018)
74. Xu, X., "Exercise and Parkinson’s disease", Int. Rev. Neurobiol, 147, pp.45~74 (2019)
75. Kainaga, M., "Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson’s Disease : an observational study", Mov. Disord, 36, pp.2461~2463 (2021)
76. Wang, Y., "Toll-like receptors mediating vascular malfunction : lessons from receptor subtypes", Pharmacol. Ther, 158, pp.91~100 (2016)
77. Botos, I., "The structural biology of Toll-like receptors", Structure, 19, pp.447~459 (2011)
78. Kawasaki, T., "Toll-like receptor signaling pathways", Front. Immunol, 5, pp.461~ (2014)
79. Piccinini, A. M., "DAMPening inflammation by modulating TLR signalling", Mediators Inflamm, 2010, pp.672395~ (2010)
80. Jin, M. S., "Structures of the toll-like receptor family and its ligand complexes", Immunity, 29, pp.182~191 (2008)
81. Okun, E., "Toll-like receptor signaling in neural plasticity and disease", Trends Neurosci, 34, pp.269~281 (2011)
82. Jana, M., "Fibrillar amyloid-beta peptides activate microglia via TLR2 : implications for Alzheimer’s disease", J. Immunol, 181, pp.7254~7262 (2008)
83. Yu, J. T., "Toll-like receptor 2-196 to-174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer’s disease", J. Neuroinflammation, 8, pp.136~ (2011)
84. Rezazadeh, M., "Genetic Factors Affecting Late-Onset Alzheimer’s Disease Susceptibility", Neuromol. Med, 18, pp.37~49 (2016)
85. Reed-Geaghan, E. G., "CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation", J. Neurosci, 29, pp.11982~11992 (2009)
86. Chen, K., "Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide", J. Biol. Chem, 281, pp.3651~3659 (2006)
87. McDonald, C. L., "Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease", Brain Behav. Immun, 58, pp.191~200 (2016)
88. Pourbadie, H. G., "Early minor stimulation of microglial TLR2 and TLR4receptors attenuates Alzheimer’s disease-related cognitive deficit in rats : behavioral, molecular, and electrophysiological evidence", Neurobiol. Aging, 70, pp.203~216 (2018)
89. Richard, K. L., "Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer’s disease", J. Neurosci, 28, pp.5784~5793 (2008)
90. Vollmar, P., "Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2", 4-dependent activation of the innate immune system, 2010, pp.185, 6338~6347
91. Doorn, K. J., "Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients", Acta Neuropathol. Commun, 2, pp.90~ (2014)
92. Frank, S., "Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice", Neurosci. Lett, 453, pp.41~44 (2009)
93. Udan, M. L., "Toll-like receptors 2 and 4mediate Abeta(1-42)activation of the innate immune response in a human monocytic cell line", J. Neurochem, 104, pp.524~533 (2008)
94. Li, X., "Single nucleotide polymorphisms in the toll-like receptor 2(TLR2)gene are associated with sporadic Parkinson’s disease in the North-eastern Han Chinese population", Neurosci. Lett, 656, pp.72~76 (2017)
95. Kalinderi, K., "TLR9-1237 T", C and TLR2-194 to-174 del polymorphisms and the risk of Parkinson’s disease in the Greek population : a pilot study, 2013, pp.34, 679~682
96. 김창윤, "Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2", Experimental Neurobiology, 25(3), pp.113~119 (2016), 한국뇌신경과학회
97. Roodveldt, C., "Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor(TLR)stimulation", PLoS ONE, 8, pp.e79160~ (2013)
98. Qiao, H., "Elevated neuronal alpha-synuclein promotes microglia activation after spinal cord ischemic", reperfused injury, 2015, pp.26, 656~661
99. Daniele, S. G., "Activation of MyD88-dependent TLR1", 2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders, 2015, pp.8, ra45~
100. Kim, N. H., "Toll-like receptor 2 downregulation and cytokine dysregulation predict mortality in patients with Staphylococcus aureus bacteremia", BMC Infect. Dis, 20, pp.901~ (2020)
101. Drouin-Ouellet, J., "Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson’s disease", Int. J. Neuropsychopharmacol, 18, pp.pyu103~ (2014)
102. La Vitola, P., "Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2", Brain Behav. Immun, 69, pp.591~602 (2018)
103. Koo, J. H., "Treadmill exercise produces neuroprotective effects in a murine model of Parkinson’s disease by regulating the TLR2", MyD88, Neuroscience, pp.2017, 356[DOI]
104. Liu, H. Y., "Innate immune responses regulate morphogenesis and degeneration : roles of Toll-like receptors and Sarm1 in neurons", Neurosci. Bull, 30, pp.645~654 (2014)
105. Kim, C., "Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy", Cell Rep, 13, pp.771~782 (2015)
106. Dzamko, N., "Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology", Acta Neuropathol, 133, pp.303~319 (2017)
107. Stefanis, L., "alpha-Synuclein in Parkinson’s disease", Cold Spring Harb. Perspect. Med, 2, pp.a009399~ (2012)
108. Fang, L., "TLR2 mediates phagocytosis and autophagy through JNK signaling pathway in Staphylococcus aureus-stimulated RAW264.7 cells", Cell. Signal, 26, pp.806~814 (2014)
109. Wang, J. P., "Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2", J. Virol, 79, pp.12658~12666 (2005)
110. Cai, M., "The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-kappaB through the Toll-like receptor 2 and MyD88", TRAF6-dependent signaling pathway, 2013, pp.8, e54586~
111. Wang, W., "Up-regulation of IL-6 and TNF-alpha induced by SARScoronavirus spike protein in murine macrophages via NF-kappaB pathway", Virus Res, 128, pp.1~8 (2007)
112. Khanmohammadi, S., "Role of Toll-like receptors in the pathogenesis of COVID-19", J. Med. Virol, 93, pp.2735~2739 (2021)
113. Frank, M. G., "SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses : Evidence of PAMP-like properties", Brain Behav. Immun, 100, pp.267~277 (2021)
114. Proud, P. C., "Prophylactic intranasal administration of a TLR2", 6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model, 2021, pp.63, 103153~
115. Koh, H. K., "Deaths From COVID-19", JAMA, 325, pp.133~134 (2021)
116. Tremblay, M. E., "Neuropathobiology of COVID-19 : the role for Glia", Front. Cell. Neurosci, 14, pp.592214~ (2020)
117. Varatharaj, A., "The blood-brain barrier in systemic inflammation", Brain Behav. Immun, 60, pp.1~12 (2017)
118. Poewe, W., "Parkinson disease", Nat. Rev. Dis. Prim, 3, pp.17013~ (2017)

관련 논문AI추천